Core Viewpoint - The company, Weikang Pharmaceutical, is expected to report a significant net loss for 2025, with projections indicating a loss between 245 million yuan and 170 million yuan, representing a year-on-year decline of 66.18% to 15.31% [1] Financial Performance - The company has experienced continuous losses for two consecutive years, with a net profit of -8.954 million yuan in 2023 and -147 million yuan in 2024 [1] - For the first three quarters of 2025, the company reported revenue of 151 million yuan, a year-on-year decrease of 59.20%, and a net profit of -124 million yuan [1] Stock Performance - The stock price has shown significant volatility, with a fluctuation range of 11.77% from February 5 to February 11, 2026, and a closing price of 28.35 yuan on February 11, reflecting a single-day increase of 2.75% [2] - The stock's trading volume indicates a net inflow of 7.4016 million yuan from major funds on February 11, with a noticeable cumulative net inflow over the past five days [2] - Technical indicators show the stock price is between the 20-day Bollinger Bands resistance level of 34.76 yuan and support level of 24.17 yuan, with the MACD indicator remaining negative but the short-term KDJ indicator rising to a neutral zone [2] Recent Events - On February 5, 2026, the company appointed a new board secretary, Wang Si, who is a "post-90s" internal promotion with no prior experience as a listed company secretary [3] - The company received a drug registration certificate from the National Medical Products Administration for its product, Er Dong Tang Granules, which is expected to enhance its product line, although the commercial impact remains to be seen [3]

Group 1 - The company announced the resignation of its Deputy General Manager, Ms. Kong Xiaoxia, due to internal adjustments, with her original term set to end on May 19, 2027 [2] - The company held its 10th meeting of the 4th Board of Directors on February 5, 2026, where it approved the appointment of Ms. Wang Si as the new Deputy General Manager and Board Secretary [2] - Following her appointment, Ms. Wang Si will no longer serve as the company's Securities Affairs Representative, and the current Chairman and General Manager, Mr. Liu Yang, will cease to act as the Board Secretary [2] Group 2 - Ms. Wu Yang has been appointed as the new Securities Affairs Representative, with her term starting from the date of the board's approval until the end of the current board's term [2]

Company Changes - Weikang Pharmaceutical announced the resignation of Ms. Kong Xiaoxia from her position as Vice General Manager, originally set to last until May 19, 2027, due to company restructuring. She will continue to hold other positions within the company [1] - The board has appointed Ms. Wang Si as the new Vice General Manager and Board Secretary. Following this appointment, Ms. Wang will no longer serve as the company's Securities Affairs Representative [1] Industry Context - The article highlights the growing issue of elderly individuals living alone, with millions affected. It discusses the concept of intended guardianship, which has been present in the country for 14 years but still faces challenges in full implementation [1]

证券代码：300878 证券简称：维康药业 公告编号：2026-004 浙江维康药业股份有限公司 关于副总经理辞职及聘任副总经理、董事会秘书和证券事务 代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于副总经理辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于近日收到公司副 总经理孔晓霞女士的书面辞职报告。因公司调整安排，孔晓霞女士申请辞去公司 副总经理职务，原定任职日期至 2027 年 5 月 19 日。辞去上述职务后仍在公司担 任其他职务。根据《公司法》《公司章程》规定，孔晓霞女士的辞职报告自送达 董事会之日起生效。 截至本公告披露日，孔晓霞女士持有公司股份 888,484 股，占公司总股本的 0.61%。孔晓霞女士辞职后，将严格遵守《上市公司董事和高级管理人员所持本 公司股份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 18 号 ——股东及董事、高级管理人员减持股份》等法律法规、规范性文件的相关要求； 孔晓霞女士不存在应履行而未履行的承 ...

一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第四届董事会第十次会议 通知于 2026 年 1 月 30 日以电子邮件、专人送达或电话方式送达全体董事，本次 会议于 2026 年 2 月 5 日在浙江省丽水经济开发区遂松路 2 号研发大楼会议室以 现场结合通讯方式召开。本次会议由董事长刘洋先生主持，公司应出席董事 7 人，实际出席董事 7 人。本次董事会会议的召集、召开和表决程序符合有关法律、 法规、部门规章、规范性文件和《公司章程》的规定，决议内容合法有效。 二、董事会会议审议情况 1、审议通过《关于聘任公司副总经理、董事会秘书的议案》 公司董事会同意聘任王思女士为公司副总经理、董事会秘书，任期自本次董 事会审议通过之日起至第四届董事会届满之日止。王思女士被聘任为公司董事会 秘书后，将不再担任公司证券事务代表职务，董事长、总经理刘洋先生将不再代 行公司董事会秘书职责。 证券代码：300878 证券简称：维康药业 公告编号：2026-003 浙江维康药业股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - Weikang Pharmaceutical has received approval from the National Medical Products Administration for the registration of a traditional Chinese medicine product, Er Dong Tang Granules, which is intended for lung and stomach health [2]. Group 1: Company Information - Weikang Pharmaceutical announced the approval of its product, Er Dong Tang Granules, which is classified as a Category 3 traditional Chinese medicine [2]. - The product is specified to contain a dosage equivalent to 12.44 grams of herbal pieces per bag [2]. - The approval number for the product is Guo Yao Zhun Zi C20260001, and it is valid until January 19, 2031 [2].

Core Viewpoint - Weikang Pharmaceutical (300878) is expected to report a net loss attributable to shareholders of between 170 million to 245 million yuan for 2025, compared to a loss of 147 million yuan in the same period last year [2] Group 1: Financial Performance - The company's capacity utilization rate is low, leading to a provision for fixed asset impairment of 45.55 million yuan [2] - The decline in product sales prices and lower-than-expected sales volume have resulted in a decrease in both operating revenue and gross margin [2] - The company has also made a provision for inventory impairment of 30.39 million yuan due to some inventory nearing expiration [2] Group 2: Regulatory Developments - The company has recently received a drug registration certificate from the National Medical Products Administration for its product, Er Dong Tang Granules, which is used for lung and stomach relief [2]

Core Viewpoint - Weikang Pharmaceutical (300878.SZ) expects a net profit attributable to shareholders of the listed company to be between -245 million to -170 million yuan for 2025, representing a year-on-year decline of 66.18% to 15.31% [1] Group 1: Financial Performance - The company has a large scale of fixed assets but low capacity utilization, leading to significant depreciation expenses that negatively impact profits [1] - The company has recognized an impairment provision for fixed assets amounting to 45.55 million yuan [1] - The sales price of the company's products has decreased, and sales volume did not meet expectations, resulting in a decline in both operating revenue and gross margin [1] Group 2: Inventory Management - Some inventory is approaching its expiration date, prompting the company to recognize an inventory impairment provision of 30.39 million yuan [1]

维康药业（300878）(300878.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损1.7亿 元至2.45亿元;扣除非经常性损益后的净亏损1.7亿元至2.45亿元。 ...